Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "combination therapy" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-10 z 10
    Tytuł:
    Atorwastatyna i ezetymib – skuteczne połączenie w terapii dyslipidemii
    Atorvastatin and ezetimibe – effective combination therapy for dyslipidemia
    Autorzy:
    Pęksa, Jan W.
    Powiązania:
    https://bibliotekanauki.pl/articles/2138887.pdf
    Data publikacji:
    2022-04-01
    Wydawca:
    Wydawnictwo Naukowe Medyk sp. z o.o.
    Tematy:
    atorvastatin
    ezetimibe
    cardiovascular risk
    chronic coronary syndromes
    combination therapy
    atorwastatyna
    ezetymib
    ryzyko sercowo-naczyniowe
    przewlekłe zespoły wieńcowe
    terapia złożona
    Opis:
    A good therapeutic option in hypercholesterolemia is the use of combination preparations containing an HMG-CoA reductase inhibitor, such as atorvastatin, and a drug that selectively inhibits the absorption of holesterol and plant sterol derivatives from the gut - ezetimibe - in a single tablet. Such treatment can be implemented in adults with primary hypercholesterolemia, familial hypercholesterolemia or mixed hyperlipidemia, which is already controlled with atorvastatin and ezetimibe as separate preparations, at the same doses as in the combination preparation. The preparation is administered 1x /day at any time, day. It is mostly a safe drug and well tolerated by patients. Possible side effects are mainly due to possible side effects of statins.
    Źródło:
    Gabinet Prywatny; 2022, 284, 04; 7-12
    2353-8600
    Pojawia się w:
    Gabinet Prywatny
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    A recently developed approach in tumor therapy using Salmonella
    Autorzy:
    Gharbavi, M.
    Karimkhanlooei, G.
    Amani, J.
    Kashiazari, P.
    Sharafi, A.
    Powiązania:
    https://bibliotekanauki.pl/articles/2097086.pdf
    Data publikacji:
    2020
    Wydawca:
    Polska Akademia Nauk. Czytelnia Czasopism PAN
    Tematy:
    cancer therapy
    combination therapy
    Salmonella
    tumor targeting
    Opis:
    There are three main approaches in cancer treatment: surgery, chemotherapy, and radiotherapy. Recently, the use of bioengineered bacteria as therapeutic agents has been shown to have some valuable properties in the treatment of cancer, which do not exist in conventional approaches. Bacteria in particular can target tumors, and they can preferentially proliferate and accumulate within tumors and inhibit the growth of cancer cells by inducing cytotoxicity. Thus, bacteria can be easily detected in tumor sites. Moreover, bacteria-derived factors exert an immunostimulatory effect. Over the past decade, Salmonella, Clostridium, and other bacterial genera have been shown to inhibit tumor growth and promote the survival rate in animal models. Clinical trials for cancer treatment with bacteria have shown improved results by combination with other therapeutic methods such as chemotherapy or radioactive agents. This review is an effort to introduce the use of healthy bacteria in tumor therapy. We specifically focus on Salmonella, which has been extensively used in tumor therapy. Therefore, in this review study, we discuss the merits, mechanisms, and attenuated strains of a combination therapy compared to other therapeutic approaches in Salmonella-mediated cancer therapy.
    Źródło:
    BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology; 2020, 101, 3; 253-267
    0860-7796
    Pojawia się w:
    BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Knowledge and attitude of primary healthcare workers towards rational prescription of artemisinin-based combination therapy in the treatment of uncomplicated malaria in Ondo State, Southwestern Nigeria
    Autorzy:
    Oyinaka, B.D.
    Umar, N.M.
    Aminu, N.
    Akinleye, C.A.
    Nuhu, T.
    Powiązania:
    https://bibliotekanauki.pl/articles/2098244.pdf
    Data publikacji:
    2020
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    Primary Health Care
    worker
    artemisinin-based combination therapy
    knowledge
    Ondo State
    Nigeria
    Opis:
    Introduction and objective. For an effective and desired outcome of therapy to be achieved, the technical capacity of the healthcare worker is a key factor. The aim of the study is to assess knowledge and attitudes of primary healthcare (PHC) workers towards rational artemisinin-based combination therapy (ACT) prescribed in the treatment of uncomplicated malaria. Materials and method. This is a descriptive cross-sectional survey in which a self-administered structured questionnaire was used. A combination of stratified and multistage sampling techniques where utilized in the selection of the healthcare workers (HCWs). Results. Of the 422 respondents, 100 (23.7%) were males and 322 (76.3%) were females. Respondents with less than five years in practice accounted for 36%, while 64% had six years and above of practice. Community health extension workers (CHEW) accounted for 54%, while 46% were either community health officers (CHO), nurses, midwives, Bachelors of Science (BSc) in community health, or with other qualifications. A total of 390 (92.4%) were aware of the availability of ACTs and used the malaria treatment protocols, whereas 28 (6.6%) still used monotherapy for simple malaria treatment, and 2.7% did not use any form of test before initiating treatment. Co-administration of non-ACTs with ACTs accounted for 12%, with 88% prescribing paracetamol with ACTs. 67% of the respondents required capacity building in rational ACT use. Conclusion. The majority of the respondents had the requisite knowledge and skills coupled with positive attitudes in prescribing ACTs. Some respondents could not distinguish between an ACTs and a monotherapy. This may affect the exact application of the malaria treatment protocols, especially at the PHC level.
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2021, 15, 1; 5-14
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    COMBINATIONS OF ISOTHIOCYANATES WITH DRUGS – A CHANCE OR THREAT TO CHEMOPREVENTION AND CANCER TREATMENT?
    Autorzy:
    Mielczarek, Lidia
    Chilmonczyk, Zdzisław
    Suchocki, Piotr
    Wroczyński, Piotr
    Wiktorska, Katarzyna
    Powiązania:
    https://bibliotekanauki.pl/articles/895549.pdf
    Data publikacji:
    2018-08-31
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    chemotherapy
    chemoprevention
    combination therapy
    sulforaphane
    isothiocyanates
    drugs combination
    Opis:
    Isothiocyanates (ITCs) are a group of compounds of natural origin which exhibit anticancer properties. In addition to the cytotoxic impact on cancer cells, confirmed in the multiple cell lines and the in vivo models, ITCs exhibit the cytoprotective effect in normal cells by regulating the activity of enzymes involved in xenobiotic metabolism. These properties of ITCs have led to a continuing increase in the number of studies which have shown that ITCs can sensitize cancer cells to cytostatic drugs used as standard in cancer therapies. On the other hand these compounds may decrease the effectiveness of drugs by deregulating the metabolising system of the cell. This paper discusses the results of preclinical study on ITCs applications in combination therapy as well as their role in drug metabolism.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 4; 829-841
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Detection of Plasmodium falciparum chloroquine resistance transporter (PfCRT) mutant gene amongst malaria-infected pregnant women in Calabar, Nigeria
    Autorzy:
    Monjol, Bernard Ekpan
    Useh, Monday Francis
    Powiązania:
    https://bibliotekanauki.pl/articles/972121.pdf
    Data publikacji:
    2017
    Wydawca:
    Polskie Towarzystwo Parazytologiczne
    Tematy:
    malaria
    chloroquine
    artemisinin-based combination therapy
    microscopy
    PCR
    PFCRT
    Opis:
    Chemotherapy is the mainstay in malaria control and management. For some time, chloroquine (CQ) was a drug of choice for the treatment of malaria. It was effective against all forms of malaria, cheap and readily available. The increased resistance of malaria parasites to CQ led to widespread abandonment of the drug in African and Asian countries on the prompting of the World Health Organization. Currently, artemisinin-based combination therapy is the gold standard for the treatment of malaria. This study investigates the presence of the Plasmodium falciparum Chloroquine Resistance Transporter (PfCRT) mutant gene, a molecular marker responsible for CQ resistance in malaria parasites. A total of 369 pregnant women were microscopically screened for malaria infection using thin and thick blood films stained with Giemsa. Subsequently, malaria parasite DNA was extracted from the blood of malaria positive participants. The PfCRT gene was amplified using Polymerase Chain Reaction (PCR). A Restriction Fragment Length Polymorphism analysis of the gene was performed to confirm mutant forms. The results showed that 251 (68.0%) of the participants had Plasmodium falciparum in their blood. Molecular examination revealed the presence of PfCRT mutant genes in 28% of the study population. Notwithstanding the decline in the prevalence of PfCRT T76 mutation since the antimalarial policy change in Nigeria, the 28% prevalence recorded in this study is considered high after ten years of the withdrawal of CQ in the treatment of uncomplicated malaria.
    Źródło:
    Annals of Parasitology; 2017, 63, 4; 323-330
    0043-5163
    Pojawia się w:
    Annals of Parasitology
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Принципы оказания помощи лицам с алкогольной зависимостью
    Principles of care for persons with alcohol dependence
    Autorzy:
    Vozniy, D.V.
    Powiązania:
    https://bibliotekanauki.pl/articles/1032344.pdf
    Data publikacji:
    2014
    Wydawca:
    Uniwersytet Kazimierza Wielkiego w Bydgoszczy
    Tematy:
    алкогольная зависимость
    медико-психологическая
    помощь
    этапность лечения
    комплексная терапия
    наркология
    alcohol addiction
    medical and psychological assistance
    stages of
    treatment
    combination therapy
    drug and alcohol abuse
    Opis:
    В статье описана этапность оказания и организация медикопсихологической помощи лицам с алкогольной зависимостью в мире. Рассмотрены основные принципы и методы лечения алкогольной зависимости, которые на данный момент являются наиболее распространенными в амбулаторной и диспансерной практике оказания помощи алкозависимым в мировой практике.
    The article describes the phasing of the provision and organization of medical and psychological care for people with alcohol dependence in the world. The basic principles and methods of treatment of alcohol dependence, which are currently the most common in the outpatient dispensary practice and assist alcohol addicted in the world.
    Źródło:
    Journal of Health Sciences; 2014, 4, 1; 303-312
    1429-9623
    Pojawia się w:
    Journal of Health Sciences
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Leczenie skojarzone astmy wziewnymi glikokortykosteroidami i β2-agonistami
    Treatment of asthma using combination of inhaled corticosteroids and β2-agonist
    Autorzy:
    Grzelewska-Rzymowska, Iwona
    Powiązania:
    https://bibliotekanauki.pl/articles/1031414.pdf
    Data publikacji:
    2009
    Wydawca:
    Medical Communications
    Tematy:
    asthma
    combination therapy
    inhaled corticosteroids
    long acting β2-agonist
    maintenance and reliever medication
    astma
    wziewne glikokortykosteroidy
    długo działający β2-agoniści
    leczenie kombinowane
    leczenie przewlekłe i „na żądanie”
    Opis:
    This review assesses the evidence regarding the use asthma-treatment with combination long-acting β2-agonist (LAβA) and inhaled corticosteroid (ICS). The first line-treatment in asthma is inhaled corticosteroid. The integral part of asthma management is β2-agonist, which present the strongest bronchodilators. Currently, two long-acting β2-agonist – salmeterol and formoterol are widely available. Recently several clinical studies have proved that LAβAs in combination with ICS are effective and safe option in asthma management. GINA guidelines recommend the addition of LAβAs to a low and medium dose ICS, when low doses of ICS do not allow to achieve control of asthma symptoms. From some clinical trials we have knowledge that LAβAs given in combination with ICS demonstrate that addition LAβAs is more beneficial in control asthma symptoms than doubling dose of ICS. Asthma is a chronic inflammatory disease of the airways with their hyperresponsiveness. The clinical course of asthma is usually different in different patients and even in the same subject. In normal clinical practice, a maintenance dose of ICS appropriate to the severity of the patient’s asthma of either combination of ICS and LAâA is administered twice daily, and a separate â2-agonist (SAâA – short acting â2-agonist) is used as needed to relieve asthma symptoms. Recently a new model of combination of ICS budesonide and LAâA (formoterol) in one inhaler has been proposed. This model is called SMART (Single Maintenance and Reliever Therapy). In this treatment concept combination budesonide/formoterol in one inhaler is used for both maintenance and as-needed therapy for symptoms relief, without a separate rescue medication. Several clinical trials have shown that SMART method reduced the risk of severe exacerbations and was well tolerated. This method has a beneficial role in patients who remain symptomatic despite treatment with combination maintenance therapy.
    Dokonany w tym artykule przegląd badań ocenia dowody dotyczące leczenia astmy kombinacją wziewnych glikokortykosteroidów (wGKS) i długo działających β2-agonistów (LAβA). Za leki pierwszego wyboru w astmie uznaje się wGKS. Integralną częścią leczenia astmy są β2-agoniści, najsilniejsze leki rozszerzające oskrzela. Obecnie dostępne są dwa leki z grupy długo działających β2-agonistów – formoterol i salmeterol. W kilku badaniach klinicznych udowodniono, że kombinacja wGKS i LAβA stanowi skuteczną i bezpieczną opcję w leczeniu astmy. Raporty GINA zalecają dodanie LAβA do małych i średnich dawek wGKS, co pozwala na uzyskanie kontroli astmy. Także z badań klinicznych uzyskaliśmy wiedzę, że kombinacja wGKS i LAβA daje większe korzyści w kontroli objawów astmy niż dwukrotnie większa dawka wGKS. Astma jest przewlekłą chorobą zapalną z rozwojem nadreaktywności oskrzeli. Przebieg kliniczny astmy jest zazwyczaj inny u różnych chorych, a nawet u tej samej osoby. W praktyce klinicznej choremu zaleca się podawanie stałych dawek wGKS, odpowiednich do stopnia ciężkości astmy, lub kombinacji wGKS i LAβA dwa razy dziennie i dodatkowo krótko działającego β2-agonisty „według potrzeby” (lub „na żądanie”) dla złagodzenia objawów astmy. Ostatnio wprowadzono nowy model stosowania kombinacji wGKS i LAβA (budezonid/formoterol) – tzw. SMART (Single Maintenance and Reliever Therapy). Jest to połączenie leków według koncepcji SMART stosowane zarówno w leczeniu przewlekłym dwa razy dziennie, jak i „według potrzeby” dla złagodzenia objawów bez dodatkowego stosowania leków tylko przynoszących ulgę. Badania kliniczne wykazały, że metoda SMART zmniejsza ryzyko ostrych zaostrzeń i jest dobrze tolerowana. Metoda ta ma korzystne działanie u pacjentów, u których utrzymują się objawy astmy pomimo leczenia kombinacją leków stosowanych tylko w leczeniu przewlekłym.
    Źródło:
    Pediatria i Medycyna Rodzinna; 2009, 5, 3; 178-185
    1734-1531
    2451-0742
    Pojawia się w:
    Pediatria i Medycyna Rodzinna
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    A practical algorithm management of patients with benign prostatic hyperplasia
    Autorzy:
    Dutkiewicz, S.
    Powiązania:
    https://bibliotekanauki.pl/articles/3168.pdf
    Data publikacji:
    2008
    Wydawca:
    Instytut Medycyny Wsi
    Tematy:
    algorithm management
    human disease
    patient
    benign prostate hyperplasia
    hyperplasia
    man
    urinary outflow obstruction
    enlargement
    prostate
    alpha1-adrenoreceptor blocker
    5-alpha-reductase inhibitor
    combination therapy
    surgical treatment
    Źródło:
    Journal of Pre-Clinical and Clinical Research; 2008, 02, 2
    1898-2395
    Pojawia się w:
    Journal of Pre-Clinical and Clinical Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors
    Autorzy:
    Jazowiecka-Rakus, Joanna
    Jarosz, Magdalena
    Kozłowska, Dorota
    Sochanik, Aleksander
    Szala, Stanisław
    Powiązania:
    https://bibliotekanauki.pl/articles/1041124.pdf
    Data publikacji:
    2007
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    combination therapy
    CTX
    anticancer
    vasostatin
    antiangiogenic
    Opis:
    Growth of tumors is strongly dependent upon supply of nutrients and oxygen by de novo formed blood vessels. Inhibiting angiogenesis suppresses growth of primary tumors as well and affects development of metastases. We demonstrate that recombinant MBP/vasostatin fusion protein inhibits proliferation of endothelial cells in vitro. The therapeutic usefulness of such intratumorally delivered recombinant protein was then assessed by investigating its ability to inhibit growth of experimental murine melanomas. In the model of B16-F10 melanoma the MBP/vasostatin construct significantly delayed tumor growth and prolonged survival of treated mice. A combination therapy involving MBP/vasostatin construct and cyclophosphamide was even more effective and led to further inhibition of the tumor growth and extended survival. We show that such combination might be useful in the clinical setting, especially to treat tumors which have already formed microvessel networks.
    Źródło:
    Acta Biochimica Polonica; 2007, 54, 1; 125-133
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumours
    Autorzy:
    Jazowiecka-Rakus, Joanna
    Jarosz, Magdalena
    Szala, Stanisław
    Powiązania:
    https://bibliotekanauki.pl/articles/1041289.pdf
    Data publikacji:
    2006
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    angiogenesis
    combination
    vasostatin
    cyclophosphamide
    gene therapy
    Opis:
    Angiogenesis, i.e. formation of new blood vessels out of pre-existing capillaries, is essential to the development of tumour vasculature. The discovery of specific antiangiogenic inhibitors has important therapeutic implications for the development of novel cancer treatments. Vasostatin, the N-terminal domain of calreticulin, is a potent endogenous inhibitor of angiogenesis and tumour growth. In our study, using B16(F10) murine melanoma model and electroporation we attempted intramuscular transfer of human vasostatin gene. The gene therapy was combined with antiangiogenic drug dosing schedule of a known chemotherapeutic (cyclophosphamide). The combination of vasostatin gene therapy and cyclophosphamide administration improved therapeutic effects in melanoma tumours. We observed both significant inhibition of tumour growth and extended survival of treated mice. To our knowledge, this is one of the first reports showing antitumour efficacy of electroporation-mediated vasostatin gene therapy combined with antiangiogenic chemotherapy.
    Źródło:
    Acta Biochimica Polonica; 2006, 53, 1; 199-202
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-10 z 10

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies